Claims

1. A bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof:



(I)

wherein

A represents



wherein

Q_1 and Q_4 independently represent direct bond or methylene;

Q_2 represents CHR^2, or CO,

Q_3 represents CHR^3, or CO,

wherein

R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that

Q_1 and Q_4 can not be direct bond at the same time;

R^2 and R^3 can not be hydrogen at the same time;

when Q_1 represents direct bond,

R^3 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_5 represents CH or CR^5,

wherein

R^5 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

Q_6 represents CH or CR^6,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy,

or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or mono-, di-, or tri- halogen;

with the proviso that Q_5 and Q_6 can not be CH at the same time;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or $-N(R^4)-$,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond; and

-Y- represents CH_2, O or NH; and

R^1 represents aryl or heteroaryl,

wherein

said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-

di(C_{1-6}alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6}alkoxycarbonyl, sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6}alkanoyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl, C_{3-8}cycloalkyl, heterocycle,

C_{1-6} alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen],

C_{1-6} alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C_{1-6} alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(C_{3-8}cycloalkyl)amino, C_{1-6} alkoxycarbonyl, C_{1-6}alkoxycarbonyl or C_{1-6} alkyl].

2. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents


or

,

Q_1 and Q_4 represent methylene;

Q_2 represents CHR^2 or CO,

wherein

R^2 represents hydrogen, hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_3 represents CHR^3 or CO,

wherein

R^3 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

Q_5 represents CH;

Q_6 represents CR^6,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by mono-, di-, or tri- halogen;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2, O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6}alkoxycarbonyl,

sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6}alkanoyl)amino, carbamoyl, C_{1-6} alkyl-carbamoyl, C_{3-8}cycloalkyl, heterocycle,

C_{1-6} alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen],

C_{1-6} alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C_{1-6} alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6} alkoxy-carbonyl, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl].

3. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



,

Q_1 represents methylene;

Q_4 represents direct bond;

Q_2 represents CHR^2 or CO,

wherein

R^2 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_3 represents CHR^3,

wherein

R^3 represents hydrogen;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2, O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6}alkoxycarbonyl, sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6}alkanoyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl, C_{3-8}cycloalkyl, heterocycle,

C_{1-6} alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen],

C_{1-6} alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C_{1-6} alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6} alkoxycarbonyl, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl].

4. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



,

Q_1 and Q_4 represents methylene;

Q_2 represents CHR^2 ,

wherein

R^2 represents hydrogen;

Q_3 represents CHR^3,

wherein

R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein R^4 is hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2, O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6}alkoxycarbonyl, sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6}alkanoyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl, C_{3-8}cycloalkyl, heterocycle,

C_{1-6} alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen],

C_{1-6} alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C_{1-6} alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6} alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6} alkoxy-carbonyl, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl].

5. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



,

Q_1 and Q_4 represent methylene;

Q_2 represents CHR^2,

wherein

R^2 represents hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_3 represents CHR^3,

wherein

R^3 represents hydrogen;

m represents an integer from 1 to 3;

p represents 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 is hydrogen or C_{1-6} alkyl ,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents CH_2, O or NH; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl or pyrimidyl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, cyano, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, N-(C_{3-8} cycloalkyl)amino, C_{1-6}alkoxycarbonyl, sulfonamide, C_{1-6} alkanoyl, N-(C_{1-6}alkanoyl)amino, carbamoyl, C_{1-6} alkylcarbamoyl, C_{3-8}cycloalkyl, heterocycle,

C_{1-6} alkyl [wherein said alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C_{1-6} alkoxycarbonyl or mono-, di-, or tri-halogen],

C_{1-6} alkoxy [wherein said alkoxy is optionally substituted by mono-, di-, or tri- halogen],

C_{1-6} alkylthio [wherein said alkylthio is optionally substituted by mono-, di-, or tri- halogen],

phenyl, benzyl and phenoxy ,

[wherein said phenyl, phenyl moiety of said benzyl or phenyl moiety of said phenoxy are optionally substituted by halogen, nitro, hydroxy, carboxy, amino, N-(C_{1-6}alkyl)amino, N,N-di(C_{1-6}alkyl)amino, N-(C_{3-8}cycloalkyl)amino, C_{1-6}alkoxy-carbonyl, C_{1-6} alkoxycarbonyl or C_{1-6} alkyl].

6. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



,

Q_5 represents CH;

Q_6 represent CR^6,

wherein

R^6 represents hydroxy, C_{1-6} alkoxy, C_{1-6} alkanoyloxy, or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

m represents an integer from 0 to 3;

p represents an integer 0 or 1;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 represents hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents NH, O or CH_2; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of halogen, nitro, C_{1-6}alkyl, trifluoroC_{1-6}alkyl, C_{1-6}alkoxy, trifluoroC_{1-6}alkoxy and C_{1-6}alkanoylamino.

7. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1,

wherein

A represents



or


,

Q_1 and Q_4 represents methylene;

Q_2 represents CHR^2 ,

wherein

R^2 represents hydrogen;

Q_3 represents CHR^3,

wherein

R^3 represents hydrogen, hydroxy, C_{1-6} alkoxy or C_{1-6} alkanoyloxy;

Q_5 represents CH;

Q_6 represents CR^6,

wherein

R^6 represents hydroxy;

m represents an integer 2;

p represents an integer 0;

-X- represents a bond, -O- or -N(R^4)-,

wherein

R^4 is hydrogen or C_{1-6} alkyl,

with the proviso that when m is 0, -X- represents a bond;

-Y- represents NH or O; and

R^1 represents phenyl, naphthyl, pyridyl, or pyrimidyl,

wherein

said phenyl, naphthyl, pyridyl, or pyrimidyl are optionally substituted by one or two of substituents selected from the group consisting of chloro, bromo, fluoro, nitro, methyl, methoxy, trifluoromethyl, trifluoroethyl, trifluoromethoxy, trifluoroethoxy, acetamido and propionylamino;

8. The bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a salt thereof as claimed in claim 1, wherein said bicyclic amide, carbamate or urea derivative of the formula (I) is selected from the group consisting of:

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-[4-(trifluoromethyl)benzyl]urea;

4-(trifluoromethyl)benzyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-3-[4-(trifluoromethyl)phenyl]propan-amide;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-(2-{[4-(trifluoromethyl)phenyl]-amino}ethyl)urea;

N-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)-N'-{2-[4-(trifluoromethyl)phenoxy]-ethyl}urea;

2-{[4-(trifluoromethyl)phenyl]amino}ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;

2-[4-(trifluoromethyl)phenoxy]ethyl(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)carbamate;and

N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea;

N-(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}ethyl)-N'-(7-hydroxy-5,6,7,8-tetrahydro-naphthalen-2-yl)urea;

N-{2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl}-N'-(7-hydroxy-5,6,7,8-tetrahydro-naphthalen-2-yl)urea;

N-(2-{[4-chloro-3-(trifluoromethyl)phenyl]amino}ethyl)-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea; and

N-{2-[4-chloro-3-(trifluoromethyl)phenoxy]ethyl}-N'-(6-hydroxy-5,6,7,8-tetrahydronaphthalen-2-yl)urea

9. A medicament comprising the bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof as claimed in claim 1 as an active ingredient.

10. The medicament as claimed in claim 9, further comprising one or more pharmaceutically acceptable excipients.

11. The medicament as claimed in claim 9, wherein said bicyclic amide, carbamate or urea derivative of the formula (I), its tautomeric or stereoisomeric form, or a physiologically acceptable salt thereof is a VR1 antagonist.

12. The medicament as claimed in claim 9 for the treatment and/or prevention of an urological disorder or disease.

13. The medicament as claimed in claim 12, wherein said urological disorder or disease is urge urinary incontinence or overactive bladder.

14. The medicament as claimed in claim 9 for the treatment and/or prevention of pain.

15. The medicament as claimed in claim 14, wherein said pain is chronic pain, neuropathic pain, postoperative pain, or rheumatoid arthritic pain.

16. The medicament as claimed in claim 9 for the treatment and/or prevention of a disorder or disease related to pain.

17. The medicament as claimed in claim 16, wherein said disorder or disease related to pain is neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.

18. The medicament as claimed in claim 9 for the treatment and/or prevention of an inflammatory disorder or disease.

19. The medicament as claimed in claim 18, wherein said inflammatory disorder or disease is asthma or COPD.

20. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an urological disorder or disease.

21. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of pain.

22. Use of compounds according to claim 1 for manufacturing a medicament for the treatment and/or prevention of an inflammatory disorder or disease.

23. Process for controlling an urological disorder or disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.

24. Process for controlling pain in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.

25. Process for controlling an inflammatory disorder or disease in humans and animals by administration of a VR1-antagonistically effective amount of at least one compound according to claim 1.